

# Antonio González Martínez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1617847/publications.pdf>

Version: 2024-02-01

118  
papers

13,781  
citations

71097

41  
h-index

22161

113  
g-index

125  
all docs

125  
docs citations

125  
times ranked

13173  
citing authors

#	ARTICLE	IF	CITATIONS
1	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 2154-2164.	27.0	1,860
2	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2495-2505.	27.0	1,854
3	Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2391-2402.	27.0	1,337
4	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428.	27.0	1,176
5	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, 16-41.	1.2	862
6	Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi24-vi32.	1.2	721
7	Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv72-iv83.	1.2	604
8	Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 689-699.	10.7	595
9	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 2-30.	2.5	515
10	Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. <i>Annals of Oncology</i> , 2019, 30, 1080-1087.	1.2	456
11	Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1066-1074.	13.7	216
12	Clinical Trials in Recurrent Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 771-775.	2.5	186
13	ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2015, 117, 559-581.	0.6	167
14	COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 561-563.	2.5	137
15	Safety and dose modification for patients receiving niraparib. <i>Annals of Oncology</i> , 2018, 29, 1784-1792.	1.2	125
16	Sparing fertility in young patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2008, 111, S101-S104.	1.4	114
17	Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. <i>Journal of Clinical Oncology</i> , 2016, 34, 1584-1593.	1.6	108
18	Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigaci3n en C3ncer de Ovario) study. <i>Annals of Oncology</i> , 2005, 16, 749-755.	1.2	106

#	ARTICLE	IF	CITATIONS
19	Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2. <i>Clinical Breast Cancer</i> , 2013, 13, 421-432.e8.	2.4	104
20	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 154, 327-353.	0.6	96
21	Ovarian low-grade serous carcinoma: A comprehensive update. <i>Gynecologic Oncology</i> , 2012, 126, 279-285.	1.4	92
22	Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR $\alpha$ )-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 379-385.	1.4	89
23	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. <i>Oncotarget</i> , 2016, 7, 56295-56308.	1.8	83
24	A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 136, 130-135.	1.4	80
25	Updates and management algorithm for neuroendocrine tumors of the uterine cervix. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 986-995.	2.5	71
26	A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 142, 62-69.	1.4	70
27	Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 2336-2342.	5.1	69
28	Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. <i>Annals of Oncology</i> , 2013, 24, 3028-3034.	1.2	66
29	FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. <i>Gynecologic Oncology</i> , 2016, 142, 597-607.	1.4	64
30	Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSIA Single-Arm Phase 3B Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 50-58.	2.5	61
31	Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. <i>Annals of Oncology</i> , 2012, 23, 1130-1137.	1.2	60
32	Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). <i>Journal of Clinical Oncology</i> , 2016, 34, 2516-2525.	1.6	60
33	The current role of neoadjuvant chemotherapy in the management of cervical carcinoma. <i>Gynecologic Oncology</i> , 2008, 110, S36-S40.	1.4	57
34	OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. <i>Annals of Oncology</i> , 2018, 29, 431-438.	1.2	54
35	Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. <i>European Journal of Cancer</i> , 2016, 69, 127-134.	2.8	49
36	Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. <i>European Journal of Cancer</i> , 2013, 49, 3831-3838.	2.8	48

#	ARTICLE	IF	CITATIONS
37	Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR $\alpha$ )-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 46-52.	1.4	48
38	What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer?. <i>Annals of Surgical Oncology</i> , 2016, 23, 1666-1673.	1.5	43
39	Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer. <i>Annals of Oncology</i> , 2017, 28, 1280-1287.	1.2	42
40	Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?. <i>Cancer</i> , 2019, 125, 4616-4622.	4.1	42
41	Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). <i>Annals of Oncology</i> , 2010, 21, 195-198.	1.2	41
42	HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?. <i>Annals of Oncology</i> , 2018, 29, 1610-1613.	1.2	40
43	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 53-60.	1.4	40
44	Final results from GCIG/ENGOT/AGO- $\text{OVAR}$ 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. <i>International Journal of Cancer</i> , 2020, 146, 439-448.	5.1	40
45	Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1050-1056.	2.5	39
46	Surgical treatment of recurrent cervical cancer: State of the art and new achievements. <i>Gynecologic Oncology</i> , 2008, 110, S60-S66.	1.4	38
47	Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. <i>Current Medical Research and Opinion</i> , 2015, 31, 1129-1137.	1.9	37
48	Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). <i>Annals of Oncology</i> , 2016, 27, 2236-2241.	1.2	32
49	$^{18}\text{F}$ -fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. <i>Clinical Cancer Research</i> , 2017, 23, 1432-1441.	7.0	32
50	Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference. <i>Annals of Oncology</i> , 2017, 28, viii30-viii35.	1.2	32
51	SEOM guidelines for cervical cancer. <i>Clinical and Translational Oncology</i> , 2015, 17, 1036-1042.	2.4	27
52	SEOM clinical guidelines for endometrial cancer (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 29-37.	2.4	27
53	Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study). <i>British Journal of Cancer</i> , 2014, 111, 1060-1064.	6.4	26
54	Lack of Association Between NOS3 Glu298Asp and Breast Cancer Risk: a Case-control Study. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 331-333.	2.5	21

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. <i>Gynecologic Oncology</i> , 2017, 144, 65-71.	1.4	21
56	A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 617-622.	2.5	21
57	Ifosfamide and Vinorelbine in Advanced Platinum-Resistant Ovarian Cancer: Excessive Toxicity with a Potentially Active Regimen. <i>Gynecologic Oncology</i> , 2002, 84, 368-373.	1.4	20
58	First-Line and Maintenance Therapy for Ovarian Cancer: Current Status and Future Directions. <i>Drugs</i> , 2014, 74, 879-889.	10.9	20
59	Minimal Macroscopic Residual Disease (0.1 cm). Is It Still a Surgical Goal in Advanced Ovarian Cancer?. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 906-911.	2.5	20
60	Current status of anti-angiogenic agents in the treatment of ovarian carcinoma. <i>Clinical and Translational Oncology</i> , 2009, 11, 589-595.	2.4	19
61	Progress Against Solid Tumors in Danger: The Metastatic Breast Cancer Example. <i>Journal of Clinical Oncology</i> , 2012, 30, 3444-3447.	1.6	18
62	Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. <i>European Journal of Cancer</i> , 2019, 117, 99-106.	2.8	17
63	Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression. <i>BMC Cancer</i> , 2015, 15, 940.	2.6	16
64	Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2009, 11, 363-375.	2.4	15
65	SEOM Clinical Guideline in ovarian cancer (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1206-1212.	2.4	15
66	Novel chemotherapy approaches in chemoradiation protocols. <i>Gynecologic Oncology</i> , 2008, 110, S45-S48.	1.4	14
67	Critically short telomeres and toxicity of chemotherapy in early breast cancer. <i>Oncotarget</i> , 2017, 8, 21472-21482.	1.8	14
68	Current management of uterine sarcomas. <i>Clinical and Translational Oncology</i> , 2011, 13, 307-314.	2.4	13
69	SEOM guideline in ovarian cancer 2014. <i>Clinical and Translational Oncology</i> , 2014, 16, 1067-1071.	2.4	13
70	Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5506-5506.	1.6	13
71	Targeting cytoskeleton reorganisation as antimetastatic treatment. <i>Clinical and Translational Oncology</i> , 2010, 12, 662-669.	2.4	12
72	Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. <i>Clinical and Translational Oncology</i> , 2013, 15, 477-483.	2.4	12

#	ARTICLE	IF	CITATIONS
73	Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?. <i>Lancet Oncology</i> , The, 2017, 18, 8-9.	10.7	12
74	Indications for adjuvant radiotherapy treatment after surgery and novel modalities for treatment. <i>Gynecologic Oncology</i> , 2008, 110, S41-S44.	1.4	11
75	Feasibility of a Modified Outpatient Regimen of Intravenous/Intraperitoneal Chemotherapy in Optimally Debulked Stage III Ovarian Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1048-1055.	2.5	11
76	Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1141-1147.	2.5	11
77	Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5508-5508.	1.6	11
78	Metastatic Endometrial Cancer in Lung and Liver: Complete and Prolonged Response to Hormonal Therapy with Progestins. <i>Gynecologic Oncology</i> , 1999, 72, 250-255.	1.4	10
79	Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice. <i>Future Oncology</i> , 2017, 13, 3-9.	2.4	10
80	Multimodality treatment in locoregional gynecological cancer: cervical cancer treatment update. <i>Annals of Oncology</i> , 2008, 19, vii70-vii76.	1.2	9
81	Update on randomized trials on recurrent disease. <i>Annals of Oncology</i> , 2013, 24, x48-x52.	1.2	9
82	Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.8	9
83	Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 628-635.	1.4	9
84	Costâ€“utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain. <i>Clinical and Translational Oncology</i> , 2019, 21, 1076-1084.	2.4	9
85	Is combination chemotherapy superior to single-agent chemotherapy in second-line treatment?. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 185-191.	2.5	7
86	Joint ENGOT and GOG Foundation requirements for trials with industry partners. <i>Gynecologic Oncology</i> , 2019, 154, 255-258.	1.4	7
87	Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 819-824.	2.5	7
88	Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting. <i>Clinical and Translational Oncology</i> , 2010, 12, 418-430.	2.4	6
89	Bevacizumab as front-line treatment for newly diagnosed epithelial cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 123-129.	2.4	6
90	Is there a role for HIPEC in ovarian cancer?. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 859-860.	1.7	6

#	ARTICLE	IF	CITATIONS
91	GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer. <i>Future Science OA</i> , 2019, 5, FSO370.	1.9	6
92	Joint ENGOT and GOG Foundation requirements for trials with industry partners. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1094-1097.	2.5	6
93	Adjuvant endocrine therapy in premenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 43-47.	2.5	5
94	Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin + pegylated liposomal doxorubicin. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 3-10.	2.4	5
95	Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2018, 20, 274-285.	2.4	5
96	Report from the European Society of Gynaecological Oncology (ESGO) 2020 State-of-the-Art Virtual Meeting. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 658-669.	2.5	5
97	Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FR $\alpha$ )-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5553-5553.	1.6	5
98	The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5560-5560.	1.6	5
99	Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)â€™ Initial safety and efficacy from expansion cohorts (ECs) of phase I study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 195-195.	1.6	5
100	Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 898-905.	2.5	4
101	Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1603-1607.	2.5	4
102	Niraparib treatment for patients with <i>BRCA</i>-mutated ovarian cancer: review of clinical data and therapeutic context. <i>Future Oncology</i> , 2022, 18, 2505-2536.	2.4	4
103	Long-term outcome of a phase II study of weekly docetaxel with a short course of estramustine and enoxaparin in hormone-resistant prostate cancer patients. <i>Clinical and Translational Oncology</i> , 2007, 9, 323-328.	2.4	3
104	The relevance of the Spanish society for medical oncology (SEOM)â€™s clinical oncology guidelines. <i>Clinical and Translational Oncology</i> , 2010, 12, 707-708.	2.4	3
105	Selective activity over a constitutively active RETâ€™variant of the oral multikinase inhibitor dovitinib: Results of the CNIOâ€™BR002 phase Iâ€™trial. <i>Molecular Oncology</i> , 2014, 8, 1719-1728.	4.6	3
106	European Network of Gynaecological Oncological Trial Groupsâ€™ requirements for trials between academic groups and industry partners â€™ a new Model D for drug and medical device development. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 730-734.	2.5	3
107	Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5514-5514.	1.6	3
108	PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5605-TPS5605.	1.6	3



#	ARTICLE	IF	CITATIONS
109	Emerging Concerns When Evidence-Based Medicine Is Translated into Real Life: The Case of Neoadjuvant Chemotherapy in Ovarian Cancer. <i>Current Oncology Reports</i> , 2013, 15, 4-6.	4.0	2
110	Chemotherapy-free treatments: are we ready for prime time?. <i>Annals of Oncology</i> , 2019, 30, 497-498.	1.2	2
111	Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5518-5518.	1.6	2
112	Lights and shadows of the tumoral marker CA-125 in ovarian cancer. <i>Clinical and Translational Oncology</i> , 2008, 10, 449-452.	2.4	1
113	Early-stage ovarian cancer management: still a challenge. <i>Clinical and Translational Oncology</i> , 2011, 13, 67-68.	2.4	1
114	El cáncer ginecológico. <i>Arbor</i> , 2015, 191, a237.	0.3	1
115	LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5538-5538.	1.6	1
116	OV21/PETROC: A Randomized Gynecologic Cancer Intergroup Phase II Study of Intraperitoneal Versus Intravenous Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery in Epithelial Ovarian Cancer. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 209-210.	0.4	0
117	Early-stage mucinous carcinoma (infiltrative type) of the ovary and fertility preservation. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 835-839.	2.5	0
118	Risk Factors for Node Affection and Recurrence in Endometrial Cancer. <i>Current Women's Health Reviews</i> , 2011, 7, 320-325.	0.2	0